These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23896100)

  • 1. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.
    Beer TM; Schellhammer PF; Corman JM; Glodé LM; Hall SJ; Whitmore JB; Frohlich MW; Penson DF
    Urology; 2013 Aug; 82(2):410-5. PubMed ID: 23896100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial.
    Antonarakis ES; Kibel AS; Yu EY; Karsh LI; Elfiky A; Shore ND; Vogelzang NJ; Corman JM; Millard FE; Maher JC; Chang NN; DeVries T; Sheikh NA; Drake CG;
    Clin Cancer Res; 2017 May; 23(10):2451-2459. PubMed ID: 27836866
    [No Abstract]   [Full Text] [Related]  

  • 3. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    Morgans AK; Chen YH; Sweeney CJ; Jarrard DF; Plimack ER; Gartrell BA; Carducci MA; Hussain M; Garcia JA; Cella D; DiPaola RS; Patrick-Miller LJ
    J Clin Oncol; 2018 Apr; 36(11):1088-1095. PubMed ID: 29522362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
    Gravis G; Marino P; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Fizazi K
    Eur J Cancer; 2014 Mar; 50(5):953-62. PubMed ID: 24424105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II, randomised, double-blind, placebo-controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH-agonist therapy.
    Richard PO; Fleshner NE; Bhatt JR; Hersey KM; Chahin R; Alibhai SM
    BJU Int; 2015 Nov; 116(5):744-52. PubMed ID: 24684534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
    Gilbert DC; Duong T; Kynaston HG; Alhasso AA; Cafferty FH; Rosen SD; Kanaga-Sundaram S; Dixit S; Laniado M; Madaan S; Collins G; Pope A; Welland A; Nankivell M; Wassersug R; Parmar MK; Langley RE; Abel PD
    BJU Int; 2017 May; 119(5):667-675. PubMed ID: 27753182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
    Beer TM; Bernstein GT; Corman JM; Glode LM; Hall SJ; Poll WL; Schellhammer PF; Jones LA; Xu Y; Kylstra JW; Frohlich MW
    Clin Cancer Res; 2011 Jul; 17(13):4558-67. PubMed ID: 21558406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial.
    Irani J; Salomon L; Oba R; Bouchard P; Mottet N
    Lancet Oncol; 2010 Feb; 11(2):147-54. PubMed ID: 19963436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
    BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy.
    Nishiyama T; Kanazawa S; Watanabe R; Terunuma M; Takahashi K
    Int J Urol; 2004 Sep; 11(9):735-41. PubMed ID: 15379937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lifestyle changes for improving disease-specific quality of life in sedentary men on long-term androgen-deprivation therapy for advanced prostate cancer: a randomised controlled trial.
    Bourke L; Gilbert S; Hooper R; Steed LA; Joshi M; Catto JW; Saxton JM; Rosario DJ
    Eur Urol; 2014 May; 65(5):865-72. PubMed ID: 24119318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.
    Nelson AM; Gonzalez BD; Jim HS; Cessna JM; Sutton SK; Small BJ; Fishman MN; Zachariah B; Jacobsen PB
    Support Care Cancer; 2016 Oct; 24(10):4159-66. PubMed ID: 27142516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized prospective trial evaluating testosterone, haemoglobin kinetics and quality of life, during and after 12 months of androgen deprivation after prostatectomy: results from the Postoperative Adjuvant Androgen Deprivation trial.
    Black PC; Basen-Engquist K; Wang X; Swartz RJ; Eddings T; Matin SF; Swanson D; Wood CG; Pisters LL; Babaian RJ; Troncoso P; Pettaway CA
    BJU Int; 2007 Jul; 100(1):63-9. PubMed ID: 17552954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.
    Gomella LG
    BJU Int; 2007 Jan; 99 Suppl 1():25-9; discussion 30. PubMed ID: 17229166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.
    Cormie P; Galvão DA; Spry N; Joseph D; Chee R; Taaffe DR; Chambers SK; Newton RU
    BJU Int; 2015 Feb; 115(2):256-66. PubMed ID: 24467669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: a study protocol.
    Baguley BJ; Skinner TL; Leveritt MD; Wright OR
    BMC Cancer; 2017 Jan; 17(1):1. PubMed ID: 28049525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy.
    Storey DJ; McLaren DB; Atkinson MA; Butcher I; Frew LC; Smyth JF; Sharpe M
    Ann Oncol; 2012 Jun; 23(6):1542-9. PubMed ID: 22007078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.
    Truong PT; Berthelet E; Lee JC; Petersen R; Lim JT; Gaul CA; Pai H; Blood P; Ludgate CM
    Can J Urol; 2006 Jun; 13(3):3139-46. PubMed ID: 16813705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
    Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
    Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.